Avlar BioVentures
15
5M
8
0.68
2
0.47
1
- Stages of investment
- Areas of investment
Summary
Avlar BioVentures is the famous VC, which was founded in 1999. The company was established in Europe in United Kingdom. The leading representative office of defined VC is situated in the Madingley.
Considering the real fund results, this VC is 7 percentage points less often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2005. This Avlar BioVentures works on 22 percentage points less the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 5 - 10 millions dollars.
The current fund was established by Alan G. Goodman. We also calculated 2 valuable employees in our database.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the Avlar BioVentures, startups are often financed by Excalibur Fund Managers, UK Innovation & Science Seed Fund, Scottish Equity Partners. The meaningful sponsors for the fund in investment in the same round are Excalibur Fund Managers, UK Innovation & Science Seed Fund, Providence Investment Company Limited. In the next rounds fund is usually obtained by Excalibur Fund Managers, UK Innovation & Science Seed Fund, Scottish Equity Partners.
For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Crescendo Biologics, Purely Proteins Limited, Takeda Cambridge. Among the most popular fund investment industries, there are Health Care, Software. The fund has specific favorite in a number of founders of portfolio startups.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 15
- Lead investments
- 2
- Exits
- 1
- Rounds per year
- 0.68
- Follow on index
- 0.47
- Investments by industry
- Biotechnology (12)
- Medical (7)
- Therapeutics (5)
- Health Care (5)
- Pharmaceutical (4) Show 7 more
- Investments by region
-
- United Kingdom (15)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Group Appearance index
- 0.87
- Avg. company exit year
- 5
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Purely Proteins Limited | 26 Nov 2003 | Biotechnology | Early Stage Venture | 0 | Cambridge, United Kingdom, England |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.